Afficher la notice abrégée

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort

dc.rights.licenseopenen_US
dc.contributor.authorMOINARD-BUTOT, Fabien
dc.contributor.authorSAINT-MARTIN, Caroline
dc.contributor.authorPFLUMIO, Carole
dc.contributor.authorCARTON, Matthieu
dc.contributor.authorJACOT, William
dc.contributor.authorCOTTU, Paul-Henri
dc.contributor.authorDIERAS, Veronique
dc.contributor.authorDALENC, Florence
dc.contributor.authorGONCALVES, Anthony
dc.contributor.authorDEBLED, Marc
dc.contributor.authorPATSOURIS, Anne
dc.contributor.authorMOURET-REYNIER, Marie-Ange
dc.contributor.authorVANLEMMENS, Laurence
dc.contributor.authorLEHEURTEUR, Marianne
dc.contributor.authorEMILE, George
dc.contributor.authorFERRERO, Jean-Marc
dc.contributor.authorDESMOULINS, Isabelle
dc.contributor.authorUWER, Lionel
dc.contributor.authorEYMARD, Jean-Christophe
dc.contributor.authorCHEAIB, Bianca
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCOURTINARD, Coralie
dc.contributor.authorBACHELOT, Thomas
dc.contributor.authorCHEVROT, Michael
dc.contributor.authorPETIT, Thierry
dc.date.accessioned2022-04-20T11:13:33Z
dc.date.available2022-04-20T11:13:33Z
dc.date.issued2022-03-11
dc.identifier.issn1532-3080 (Electronic) 0960-9776 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/139873
dc.description.abstractEnPURPOSE: Trastuzumab-emtansine (T-DM1), as well as lapatinib plus capecitabine were proven effective in two Phase III studies, following first-line trastuzumab plus a taxane. The introduction of dual HER2 blockade by trastuzumab and pertuzumab as first-line has positioned T-DM1 into second-line, and lapatinib plus capecitabine beyond, without formal evaluation of these strategies. METHODS: ESME Data Platform (NCT03275311) included individual data from all patients aged ≥18 years, in whom first-line treatment for metastatic breast cancer (MBC) was initiated between January 1, 2008 and December 31, 2016 in one of the 18 French Comprehensive Cancer Centers. The efficacy of T-DM1 and lapatinib plus capecitabine combination, following double blockade associating trastuzumab and pertuzumab were evaluated in this national real-life database. Eligibility criteria were: female, MBC, HER2+ tumor, first-line taxane-based chemotherapy and dual HER2-blockage by trastuzumab plus pertuzumab. Cohort A received second-line T-DM1, and Cohort B second-line T-DM1 and third or fourth-line lapatinib plus capecitabine. RESULTS: Cohort A comprised 233 patients, and Cohort B 47 patients. Median progression-free survival (PFS) was 7.1 months in Cohort A and 4.6 months in Cohort B. Median overall survival were 36.7 months and 12.9 months, respectively. PFS was significantly dependent on the preceding treatment line's duration. In cohort A, HER2 expression status was a significant predictive factor of PFS. CONCLUSION: First-line trastuzumab plus pertuzumab do not markedly diminish T-DM1's efficacy in second-line. Similarly, sequential treatment with trastuzumab plus pertuzumab then T-DM1 does not noticeably modify the efficacy of lapatinib plus capecitabine.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enDual HER2 blockade
dc.subject.enLapatinib
dc.subject.enMetastatic breast cancer
dc.subject.enOverall survival
dc.subject.enProgression-free survival
dc.subject.enT-DM1
dc.title.enEfficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.breast.2022.03.004en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed35299035en_US
bordeaux.journalBreasten_US
bordeaux.page54-60en_US
bordeaux.volume63en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDRocheen_US
bordeaux.identifier.funderIDPfizeren_US
bordeaux.identifier.funderIDAstraZenecaen_US
bordeaux.identifier.funderIDEisaien_US
bordeaux.identifier.funderIDDaiichi-Sankyoen_US
hal.identifierhal-03647242
hal.version1
hal.date.transferred2022-04-20T11:13:37Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Breast&rft.date=2022-03-11&rft.volume=63&rft.spage=54-60&rft.epage=54-60&rft.eissn=1532-3080%20(Electronic)%200960-9776%20(Linking)&rft.issn=1532-3080%20(Electronic)%200960-9776%20(Linking)&rft.au=MOINARD-BUTOT,%20Fabien&SAINT-MARTIN,%20Caroline&PFLUMIO,%20Carole&CARTON,%20Matthieu&JACOT,%20William&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_Breast_2022_Moinard-Butot.pdf
Taille:
1.802Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
811octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée